Thomas Powles
Impact in
Papers in
- Co-authors
- Yohann Loriot (73 shared papers)Daniel S. Chen (5 shared papers)Nicholas J. Vogelzang (17 shared papers)Joaquim Bellmunt (77 shared papers)Daniel P. Petrylak (52 shared papers)Priti S. Hegde (12 shared papers)Gregg Fine (8 shared papers)Xiaodong Shen (10 shared papers)
- Journals
- Journal of Clinical Oncology (133 papers)Annals of Oncology (52 papers)European Urology (21 papers)European Urology Oncology (7 papers)British Journal of Urology (7 papers)
- Partner nations
- United KingdomUnited StatesFrance
In The Last Decade
Thomas Powles
324 papers receiving 11.0k citations
Thomas Powles's Hit Papers
Peers
Comparison fields: 5 of 122
- Oncology 4.6k
- Surgery 5.0k
- Immunology 1.6k
- Pulmonary and Respiratory Medicine 2.3k
- Cancer Research 785
Countries citing papers authored by Thomas Powles
This map shows the geographic impact of Thomas Powles's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Powles with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Powles more than expected).
Fields of papers citing papers by Thomas Powles
This network shows the impact of papers produced by Thomas Powles. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Powles. The network helps show where Thomas Powles may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas Powles, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 343 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Hit paper breakdown → | 2014 | 1860 |
| 2 | Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma Hit paper breakdown → | 2021 | 709 |
| 3 | The cancer-immunity cycle: Indication, genotype, and immunotype Hit paper breakdown → | 2023 | 516 |
| 4 | Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study Hit paper breakdown → | 2016 | 412 |
| 5 | 2017 | 279 | |
| 6 | 2008 | 268 | |
| 7 | 2014 | 219 | |
| 8 | Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer Hit paper breakdown → | 2020 | 204 |
| 9 | Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial Hit paper breakdown → | 2022 | 170 |
| 10 | 2011 | 151 | |
| 11 | 2017 | 143 | |
| 12 | 2000 | 142 | |
| 13 | 2019 | 136 | |
| 14 | 2015 | 132 | |
| 15 | Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up Hit paper breakdown → | 2023 | 124 |
| 16 | 2020 | 113 | |
| 17 | Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up Hit paper breakdown → | 2022 | 109 |
| 18 | 2008 | 108 | |
| 19 | 2019 | 101 | |
| 20 | 2020 | 100 |
About Thomas Powles
Thomas Powles is a scholar working on Surgery, Oncology, Pulmonary and Respiratory Medicine, Epidemiology and Molecular Biology, having authored 343 papers that have together received 11.2k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (240 papers), Cancer Immunotherapy and Biomarkers (141 papers), Urinary and Genital Oncology Studies (91 papers), Renal cell carcinoma treatment (55 papers), Multiple and Secondary Primary Cancers (32 papers), Testicular diseases and treatments (16 papers), Esophageal Cancer Research and Treatment (16 papers) and Prostate Cancer Treatment and Research (15 papers). The work is most often cited by research in Oncology (4.6k citations), Surgery (5.0k citations), Immunology (1.6k citations), Pulmonary and Respiratory Medicine (2.3k citations) and Cancer Research (785 citations). Thomas Powles has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Yohann Loriot, Daniel S. Chen, Nicholas J. Vogelzang, Joaquim Bellmunt, Daniel P. Petrylak, Priti S. Hegde, Gregg Fine, Xiaodong Shen, Howard A. Burris and Fadi S. Braiteh. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Urology, European Urology Oncology and British Journal of Urology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.